Cresco Labs earnings date
Cresco Labs (6CQ) Q3 2026 Earnings Report
DE:6CQ Q3 2026 EPS Results
- Actual EPS
- -EUR 0.03
- Consensus EPS
- -EUR 0.01
- Beat/Miss
- Missed by -EUR 0.01
- One Year Ago EPS
- -EUR 0.05
DE:6CQ Q3 2026 Revenue Results
- Actual Revenue
- EUR 153.75M
- Expected Revenue
- EUR 157.55M
- Beat/Miss
- Missed by -EUR 3.81M
- YoY Revenue Growth
- +6.51%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/06/2026
- Time
- Before Open
- Conference Call
- Friday, November 6, 2026
Cresco Labs's next earnings date is estimated for March 17, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive: Cresco delivered its planned Q3 results, grew revenue, generated $21 million of free cash flow, expanded its Pennsylvania and Ohio retail footprints, launched new products and reported strong market share and productivity positions. Near-term challenges include 47% gross margin affected by higher-cost inventory, expected low-single-digit sequential revenue decline in Q4, pricing and promotional pressure, a measured Kentucky ramp and uncertainty around hemp, Texas and Pennsylvania regulatory developments.
For Q4, Cresco expects net revenue to be down low single digits sequentially, gross margin similar to this quarter as the majority of the higher cost inventory from the construction period sells through, and adjusted SG&A to be up modestly in dollar terms as it rebrands acquired Pennsylvania dispensaries and opens its new dispensary in Kentucky; the Q3 framework had called for gross margin in the high 40s, adjusted SG&A essentially flat in dollar terms and adjusted EBITDA margin of approximately 20%, while higher cost inventory is expected to sell through through the rest of the year and a little bit into Q1, Kentucky’s contribution in the near term will be modest, and the Kentucky market is expected to play out through '27 and into '28.
- Q3 Revenue and Cash Flow GrowthQ3 revenue was $173 million, up 5% year-over-year and roughly flat sequentially. The company generated $26 million in operating cash flow, up from $15 million in Q2, and $21 million in free cash flow.
- Adjusted EBITDA and Free Cash Flow ConversionAdjusted EBITDA was $35 million, representing a 20% margin. The business converted over 60% of adjusted EBITDA into free cash flow during the quarter.
- Pennsylvania Acquisition and Retail ScaleCresco closed the acquisition of 9 Pennsylvania dispensaries on September 2. With 27 locations and the #1 branded share, the company operates the largest retail network in Pennsylvania, the second-largest medical market in the country.
- Ohio Retail Expansion and Cultivation ImprovementsCresco captured a full quarter of contribution from its completed 8-store Ohio retail network and upgraded cultivation facilities. The company transitioned Ohio greenhouses to full environmental control and under-canopy lighting, with current harvests showing materially higher yields.
- Massachusetts Cultivation ImprovementsCresco made cultivation improvements in Massachusetts similar to those completed in Ohio. The company stated that current harvests are showing the benefit of these investments and that additional supply should support expanded product sizes and categories in 2027.
- Ohio Market Growth and Hemp EnforcementThe Ohio market was described as up over 30% year-over-year. Cresco said Ohio's enforcement of intoxicating hemp rules can serve as a successful case study for other states, with consumers embracing lab-tested, accurately labeled products sold through regulated retail channels.
- Kentucky Commercial LaunchCresco completed its first full quarter of commercial sales in Kentucky, with the market developing broadly in line with the expected ramp-up. The company also opened its first Sunnyside dispensary in Kentucky on October 23.
- Strong Retail ProductivitySunnyside dispensaries generate nearly 30% more revenue per store than state averages. This productivity supports a top-two retail share position in Illinois, Ohio and Pennsylvania.
- Branded Product Market Share LeadershipCresco expanded its #1 branded product market share lead in Pennsylvania. In Illinois, it leads the state in flower, edibles and concentrates market share, and in Massachusetts it leads market share, led by branded flower.
- Premium Vape PositioningAlthough Cresco lost share in Illinois vape, management said this was by design because larger formats sold at the same price have pushed price per gram down by more than 1/3 in two years. Cresco's vape portfolio commands the highest price per gram of any major producer in the state.
- New SLIPS Product LaunchCresco launched SLIPS, an oral pouch under the High Supply brand, on Sunnyside shelves in Illinois in 4- and 10-milligram formats. Management said consumers are already enthusiastic about the discreet, convenient and fast-acting format.
- Wonder Beverage Mix LaunchThe Wonder brand introduced 5-milligram single-serving beverage mixes for occasions such as exercising, sleeping and socializing. The formulations include ingredients such as creatine and caffeine in the exercise product and chamomile and melatonin in the sleep product.
- Data-Driven Innovation StrategyCresco is initially launching the new products in its own Illinois stores so its retail and loyalty data can measure repeat purchases precisely. Management described the approach as test-and-learn and said it will scale using that data.
- Operating Efficiency and AI DeploymentAdjusted SG&A declined by $1 million to $54 million, or 31% of revenue, from $55 million, or 32% of revenue, in Q2. Productivity gains across the base business and corporate functions, including continued deployment of AI and automation, offset growth-related costs.
- Positive Pennsylvania Adult-Use PositioningManagement said Pennsylvania's election results improved the prospects for adult-use legalization, citing a supportive governor, House and Democratic-controlled Senate. Cresco has a second Pennsylvania facility with an opportunity for investment to increase capacity and said it will evaluate additional opportunities.
- Corporate Simplification and U.S. Exchange PreparationShareholders approved three special resolutions, each with more than 94% of votes cast in favor. Management said the resolutions simplify the corporate structure, align the company with the U.S. investor base and prepare Cresco for a potential uplisting to a senior U.S. exchange.
- Federal and Election BackdropCresco's medical operations began receiving DEA registrations under Schedule III, while the administrative process on broader rescheduling continues. Management also said election results across the country, including in Pennsylvania, Wisconsin, North Carolina and Ohio, were encouraging for regulated cannabis.
- Core Business and Efficiency Priorities for 2027For 2027, Cresco is prioritizing cash flow and plans to find scale and efficiencies across its core business. Management said it is reviewing every area of the organization for untapped opportunities to improve productivity and profitability while incorporating AI and other transformative technology solutions.
DE:6CQ Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 17, 2027 | 2026 (Q4) | -0.02- | -0.22 | ― | ― |
| Nov 06, 2026 | 2026 (Q3) | -0.01-0.03 | -0.05 | 40.00% (+0.02) | |
| Aug 06, 2026 | 2026 (Q2) | -0.010.04 | -0.04 | 202.56% (+0.07) | |
| May 08, 2026 | 2026 (Q1) | -0.02-0.04 | -0.04 | 0.00% (+0.00) | |
| Mar 05, 2026 | 2025 (Q4) | -0.01-0.22 | 0 | ― | |
| Nov 05, 2025 | 2025 (Q3) | -0.03-0.05 | -0.02 | -150.00% (-0.03) | |
| Aug 07, 2025 | 2025 (Q2) | -0.03-0.04 | -0.13 | 73.47% (+0.10) | |
| May 30, 2025 | 2025 (Q1) | -0.02-0.04 | -0.01 | -300.00% (-0.03) | |
| Mar 12, 2025 | 2024 (Q4) | -0.000.00 | 0.01 | -100.00% (-0.01) | |
| Nov 08, 2024 | 2024 (Q3) | 0.01-0.02 | -0.26 | 93.10% (+0.24) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


